Direct‐acting oral anticoagulants and alopecia: The valuable support of postmarketing data. Issue 8 (18th February 2020)

• Record Type: Journal Article
• Authors: Bonaldo, Giulia; Vaccheri, Alberto; Motola, Domenico
• Is Part Of: British journal of clinical pharmacology. Volume 86:Issue 8(2020)
• Page Start: 1654
• Page End: 1660
• Publication Date: 2020-02-18
• Subjects: adverse drug reactions -- alopecia -- direct‐acting oral anticoagulants -- drug safety -- pharmacovigilance; Pharmacology -- Periodicals; Drugs -- Periodicals; 615.1
• DOI: 10.1111/bcp.14221
• Languages: English
• ISSNs: 0306-5251

Abstract

Abstract : Little is known about the administration of direct‐acting oral anticoagulants (DOACs) and the occurrence of alopecia. Our aim was to analyse the reports of alopecia following DOAC administration received until 2 May 2018 from VigiBase, the World Health Organization database. A descriptive analysis of age, sex, seriousness and dechallenge/rechallenge outcome was carried out. For each report, the time‐to‐onset was evaluated and the causality was assessed by using Naranjo algorithm. Overall, 1316 reports were retrieved, most concerning rivaroxaban (58.8%); 80% of the reports were related to females, in particular to those aged ≥65 years (23.1%). The median value of the time‐to‐onset was 28 days, with an interquartile range of 63 days. In 54.3% of the reports the causality was assessed as possible. In conclusion, a possible association could exist between DOACs administration and alopecia, but further observational studies are needed to confirm these findings.